Suppr超能文献

全长和裂解形式的尿激酶型纤溶酶原激活物可溶性受体在卵巢癌囊液中高浓度存在。

Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.

作者信息

Wahlberg K, Høyer-Hansen G, Casslén B

机构信息

Department of Obstetrics and Gynecology, University Hospital, Lund, Sweden.

出版信息

Cancer Res. 1998 Aug 1;58(15):3294-8.

PMID:9699658
Abstract

We assayed the levels of soluble urokinase plasminogen activator receptor (su-PAR) with an ELISA in various body fluids from 77 patients with benign or malignant ovarian tumors, histologically classified as follows: benign; possibly malignant (borderline); and well, intermediately, and poorly differentiated malignant. The concentration of su-PAR in fluid from malignant cysts was extremely high, approximately 10-fold higher than the concentration in ascitic fluid and approximately 100-fold higher than that in blood. Also, the concentration in malignant cysts was approximately 10-fold higher than the concentration in benign cysts. Such high concentrations of su-PAR were found not only in truly malignant but also in possibly malignant cysts. Thus, we suggest that the concentration of su-PAR in cystic fluid can serve as a marker, allowing early diagnosis of malignant ovarian cysts. The concentration of su-PAR in fluid aspirated transvaginally with ultrasonographic guidance can be used to discriminate possibly and truly malignant cysts from benign cysts without surgery. The high concentrations of su-PAR in ovarian cystic fluids allowed us to characterize the molecular forms. Cross-linking of a radiolabeled ligand to the receptor demonstrated that at least a fraction of su-PAR was able to bind the ligand. A cleaved form of the receptor constituting domains 2 and 3 was detected with Western blotting. The cleaved receptor, which is devoid of the ligand-binding domain 1, has not previously been demonstrated in body fluids; it has only been demonstrated on cell surfaces. su-PAR domains 2 and 3 were found in cystic fluids from both malignant and benign ovarian tumors.

摘要

我们采用酶联免疫吸附测定法(ELISA)检测了77例良性或恶性卵巢肿瘤患者各种体液中可溶性尿激酶型纤溶酶原激活物受体(su-PAR)的水平,这些肿瘤在组织学上分类如下:良性;可能恶性(交界性);以及高分化、中分化和低分化恶性肿瘤。恶性囊肿液中su-PAR的浓度极高,比腹水浓度高约10倍,比血液浓度高约100倍。此外,恶性囊肿中的浓度比良性囊肿中的浓度高约10倍。不仅在真正的恶性囊肿中,而且在可能恶性的囊肿中都发现了如此高浓度的su-PAR。因此,我们认为囊肿液中su-PAR的浓度可作为一种标志物,有助于早期诊断恶性卵巢囊肿。在超声引导下经阴道抽吸的液体中su-PAR的浓度可用于在不进行手术的情况下区分可能的和真正的恶性囊肿与良性囊肿。卵巢囊肿液中高浓度的su-PAR使我们能够对其分子形式进行表征。放射性标记配体与受体的交联表明,至少一部分su-PAR能够结合该配体。通过蛋白质印迹法检测到了由结构域2和3组成的受体裂解形式。这种缺乏配体结合结构域1的裂解受体此前尚未在体液中得到证实;仅在细胞表面得到证实。在恶性和良性卵巢肿瘤的囊肿液中均发现了su-PAR结构域2和3。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验